医学
骨闪烁照相术
闪烁照相术
核医学
心肌病
内科学
放射科
心力衰竭
作者
Hendrea S. A. Tingen,Milou Berends,Alwin Tubben,Peter van der Meer,Riemer H. J. A. Slart,Johannes Bijzet,Paul A. van der Zwaag,Christoph Richard Kimmich,Christian Knackstedt,Friso L. H. Muntinghe,Ewout J. Houwerzijl,Bouke P. C. Hazenberg,Hans L. A. Nienhuis
标识
DOI:10.1007/s00259-025-07328-6
摘要
PURPOSE: Tc]Tc- hydroxydiphosphonate bone scintigraphy have or develop ATTR-CM. METHODS: This retrospective observational study was conducted at the Groningen Amyloidosis Centre of Expertise between April 2012 and June 2023. TTRv carriers with Perugini grade 1 uptake on bone scintigraphy were followed until to June 2024. Data on symptoms, biomarkers, imaging, and biopsies were collected. A descriptive analysis was performed to evaluate whether carriers met the diagnostic criteria for ATTR-CM or 'probable ATTR-CM' at baseline and follow-up. RESULTS: Out of 178 TTRv carriers in screening, 12 carriers had Perugini grade 1 cardiac radiotracer uptake on bone scintigraphy. At baseline, 2 carriers met the diagnostic criteria for ATTR-CM and 3 carriers met the criteria for probable ATTR-CM. Of the 7 carriers without (probable) ATTR-CM at baseline, 3 carriers were diagnosed with ATTR-CM during follow-up and 1 carrier developed probable ATTR-CM during follow-up. Three carriers showed signs of cardiomyopathy during follow-up, but did not meet the criteria for (probable) ATTR-CM. One of these cases may have been false-positive due to hydroxychloroquine use. CONCLUSION: Our findings suggest that Perugini grade 1 cardiac radiotracer uptake is an early marker of ATTR-CM in TTRv carriers, potentially enabling earlier diagnosis and intervention.
科研通智能强力驱动
Strongly Powered by AbleSci AI